Abstract:Yuting Wang, *,1 Rui Zhang *,2 Yanjiao Shen, 1,3 Lin Su, 1 Birong Dong, 1 Qiukui Hao 1 1 The Center of Gerontology and Geriatrics/National Center for Geriatric Clinical Research, West China Hospital, Sichuan University, Chengdu, People's Republic of China; 2 Health Informatics Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China; 3 Sleep Medicine Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China *These authors contributed equally to this work Objectives: To assess the role of a pre-chemotherapy frailty index based on routine laboratory data in predicting mortality and chemotherapy adverse reactions among older patients with primary lung cancer. Design: Retrospective cohort study Setting: West China Hospital, Chengdu, China Participants: We included patients aged ≥60 years with primary lung cancer receiving the first course of chemotherapy. Measurements: Data were collected from medical records, local government death databases or telephone interviews. Outcomes included chemotherapy adverse reactions and all-cause mortality. We constructed a frailty index based on 44 laboratory variables (FI-LAB) before chemotherapy, and chose the following cutoff points: robust (0.0–0.2), pre-frail (0.2–0.35) and frail (≥0.35). Results: We included 1,020 patients (71.4% male; median age: 65 years old). Both pre-frailty and frailty was associated with any chemotherapy adverse reactions and infections during chemotherapy (OR=3.48, 95%CI: 1.77–6.87; OR=3.58, 95%CI: 1.55–8.26, respectively). Frail patients had a shorter median overall survival rate compared to robust patients (18.05 months vs 38.89 months, log-rank p <0.001). After adjusting for some potential confounding variables, the risk of all-cause mortality was dramatically increased in frail patients (HR:2.13, 95% CI:1.51–3.00) with an average follow-up of 3.9 years. Each 0.01 or per standard deviation (SD) increase in the FI-LAB value significantly increased the HR of death by 2.0% (HR:1.02, 95% CI: 1.01–1.03) and 23.0% (HR: 1.23, 95% CI: 1.13–1.34), respectively. Conclusions: Frailty assessed by routine laboratory data indicates increased risks of chemotherapy adverse reactions and death in older patients with primary lung cancer receiving the first course of chemotherapy. Keywords: frailty, prognosis, older patients, lung cancer, chemotherapy

Association Between PD‐1 Inhibitor‐related Adverse Events and Frailty Assessed by Frailty Index in Lung Cancer Patients

Development and Validation of a Risk-Prediction Model for Immune-Related Adverse Events in Patients with Non-Small-cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors.

Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study

The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer

Predictors of Immune Checkpoint Inhibitor-Related Adverse Events in Older Patients with Lung Cancer: a Prospective Real-World Analysis

Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis

Clinical Features and Determinants of Disease Severity of Immune Checkpoint Inhibitor-Related Pneumonitis: A Retrospective Study

Age-Associated Changes in Adverse Events Arising From Anti-PD-(L)1 Therapy

Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies

Identifying Risk Factors and Biomarkers for Severe CIP in Lung Cancer Patients- a Retrospective Case Series Study.

Clinical Outcomes and Risk Factor of Immune Checkpoint Inhibitors-Related Pneumonitis in Non-Small Cell Lung Cancer Patients with Chronic Obstructive Pulmonary Disease

Clinical implications of frailty assessed in hospitalized patients with acute-exacerbation of interstitial lung disease

Analysis of the association between immune-related adverse events and the effectiveness in patients with advanced non-small-cell-lung cancer

Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China

The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials

Prediction of chemotherapy adverse reactions and mortality in older patients with primary lung cancer through frailty index based on routine laboratory data

Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study

Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis